Author:
Jacob Yanite,Schneider Bill,Spies Claudia,Heinrich Maria,von Haefen Clarissa,Kho Widuri,Pohrt Anne,Müller Anika
Abstract
AbstractDexmedetomidine is an alpha-2 adrenoreceptor agonist with anti-inflammatory and anti-delirogenic properties. Pathogenesis of postoperative delirium (POD) includes cholinergic dysfunction and deregulated inflammatory response to surgical trauma. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are discussed as biomarkers for both POD and severity in acute inflammation. To show whether there is a link between blood cholinesterase activities and dexmedetomidine, we performed a secondary analysis of a randomised, double-blind, placebo-controlled trial that recently showed a lower incidence of POD in the dexmedetomidine group. Abdominal or cardiac surgical patients aged ≥ 60 years were randomised to receive dexmedetomidine or placebo intra- and postoperatively in addition to standard general anaesthesia. We analysed the course of perioperative cholinesterase activities of 56 patients, measured preoperatively and twice postoperatively. Dexmedetomidine resulted in no change in AChE activity and caused a rapid recovery of BChE activity after an initial decrease, while placebo showed a significant decrease in both cholinesterase activities. There were no significant between-group differences at any point in time. From these data it can be assumed that dexmedetomidine could alleviate POD via altering the cholinergic anti-inflammatory pathway (CAIP). We advocate for further investigations to show the direct connection between dexmedetomidine and cholinesterase activity.
Funder
Orionin Tutkimussäätiö
DFKC
BIH Charité Digital Clinician Scientist Program funded by the Charité–Universitätsmedizin Berlin and the Berlin Institute of Health at Charité
Charité - Universitätsmedizin Berlin
Publisher
Springer Science and Business Media LLC
Reference75 articles.
1. Lee, S. Dexmedetomidine: present and future directions. Korean J. Anesthesiol. 72(4), 323–330 (2019).
2. Nelson, L. E. et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 98(2), 428–436 (2003).
3. Gurbet, A. et al. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can. J. Anaesth. 53(7), 646–652 (2006).
4. Ngwenyama, N. E. et al. Effects of dexmedetomidine on propofol and remifentanil infusion rates during total intravenous anesthesia for spine surgery in adolescents. Paediatr. Anaesth. 18(12), 1190–1195 (2008).
5. Soliman, R. N. et al. Prospective, randomized study to assess the role of dexmedetomidine in patients with supratentorial tumors undergoing craniotomy under general anaesthesia. Middle East J. Anaesthesiol 21(3), 325–334 (2011).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献